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Background & objectives: Three countries, Bangladesh, India and Nepal, set out to eliminate kala-azar 
by 2015. This study was aimed to document the knowledge and practices in kala-azar case management 
of public and private health providers in these three countries.
Methods: A health care provider survey was conducted in 2007 at 4 study sites, viz., Muzaffarpur and 
Vaishali districts in India, Mahottari district in Nepal, and Rajshahi district in Bangladesh. Interviews 
were conducted with formal and informal health care providers at their home or practice. 
Results: About half of the providers in India and Nepal knew the rapid diagnostic test rK39 recommended 
by the elimination initiative, but this was not in Bangladesh. Knowledge of the recommended first-line 
drug, miltefosine, was good in India and Nepal but less so in Bangladesh.
Interpretation & conclusions: Innovative tools for VL care have not yet been fully taken up by private 
for profit care providers in the three countries that launched a VL elimination initiative. The elimination 
initiative needs to address these gaps in private providers’ knowledge, given their substantial share in 
the care of VL patients.
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 Sixty per cent of the world’s cases of visceral 
leishmaniasis (VL) or kala-azar occur in a well-
defined area in North-east India (mainly in Bihar 
State, extending to Jharkand and West Bengal), and in 
adjacent regions in Nepal and Bangladesh. The World 
Health Organization estimates that the annual number of 
cases in this region is about 100,0001. Epidemiological 
surveillance figures in the region-based on patients 
reporting to the public sector only, are considered an 
underestimate of the true number of VL cases with a 
factor up to 82. 
 In 2005 the governments of India, Bangladesh and 
Nepal decided to eliminate VL by 2015. Elimination 
of this anthroponotic disease is deemed achievable 
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because technological innovation has paved the way: a 
rapid diagnostic test, rK39, and an oral drug, miltefosin, 
are now available3. Accordingly to Murray “the real 
obstacle now, almost entirely a matter of cost, is proper 
translation, distribution, and expansion of the advances 
that have been made so that they can have an effect in 
the field and save lives”4. While this emphasis on budget 
allocation is correct, one should not underestimate 
the need for proper translation of technical advances 
to the local context. A correct analysis of the health 
system challenges will be critical to the elimination 
target, as VL control hinges for a major part on early 
case detection and treatment5. Therefore, TDR/WHO 
initiated a number of studies to examine the community 
and health services perspective on this disease, as part 
of its support to the elimination initiative.
 While several investigators have addressed the 
community perception of kala-azar6-8 only a few have 
analysed that of the health care providers. Ahluwalia et 
al6 pointed to the huge challenge health professionals 
faced in Bangladesh when specific kala-azar drugs 
were no longer available in that country. Sundar et 
al9 showed a clear need to revise control approaches 
if early and more exhaustive case detection is to be 
achieved. Passively waiting in poorly attended public 
health clinics will not bring disease spread to a halt. 
There is a need for a much more active approach, and 
it will need to consider the available human resources 
that could potentially be mobilized for the effort. 
 The objectives of this study were to assess kala-azar 
related knowledge and practices of health providers 
practicing in the endemic areas in the three countries, 
India, Bangladesh and Nepal.
Material & Methods
 This multi-country study was conducted in 2007 
to assess the knowledge and practice in kala-azar 
management of health care providers working in 
endemic areas in Bangladesh, India, and Nepal, the 
region presently targeted by the kala-azar elimination 
initiative. This region is far from homogeneous, and 
the epidemiological picture of the disease varies 
substantially across the countries and even within 
countries. VL foci in Muzaffarpur district in India report 
very high kala-azar incidence rates, approximating 1 
per cent per year2. Vaishali district in India, Rajshahi 
in Bangladesh and Mahottari district in Nepal report 
lower incidence rates in the realm of 1 to 2 per 1000 per 
year9, though the difference might be due to the level 
of aggregation of the data. Also, the health systems 
vary substantially. In India, patients will preferentially 
consult private practitioners or one of the not-for-profit 
private clinics in Muzaffarpur town specializing in 
kala-azar treatment. In Nepal, kala-azar care is fairly 
well available in the public health services, at primary 
as well as secondary level10. In Bangladesh in 2007 the 
situation was characterized by a dramatic shortage of 
antileishmanial drugs and diagnostics at all levels of 
the public health service.
Sampling approach: We purposefully selected the 4 
study sites in Muzaffarpur and Vaishali districts in India 
(about 31,800 population each), in Mahottari district 
in Nepal (17,241 population) and Rajshahi district in 
Bangladesh (25,470 population) to maximally reflect 
the regional heterogeneity. Health care providers 
working in the study area were identified through 
several sources; for the formal sector existing lists 
were used, while providers in the informal sector were 
identified during an exhaustive household survey in 
the area10 and by snowballing techniques11. The aim 
was to select a purposive sample of 100 health care 
providers from these lists in each study site, including 
approximately equal numbers of providers practicing 
modern allopathic medicine, those practicing other 
systems of medicine, and those without medical degree 
(paramedicals and others). 
Data collection: Current and retrospective data were 
collected cross-sectionally using the same semi-
structured and pre-tested questionnaires at each 
of the four sites. Information regarding provider 
characteristics, number of VL cases treated, their 
knowledge and their actual practice in the field of 
diagnosis, treatment and referral of kala-azar cases 
was collected. The interviewers were trained before 
the survey in order to ensure uniform data collection 
practices.
Categories of health care providers: In India, the 
formal public health system includes the facilities 
established under the ‘Indian System of Medicine’ such 
as Ayurveda, Unani and Homeopathy. For the purpose 
of this study, health care providers in the three countries 
were categorized as ‘formal’ if they had a recognized 
medical or para-medical degree. This included 
allopathic doctors employed in government health 
services as well as those working in private institutions 
or in own private practice and those formally trained 
in indigenous medical systems (Ayurveda or others). 
All unqualified care providers were categorized as 
‘informal’, including traditional healers as herbalists 
and faith healers , but also local chemists and the 
so-called “jhola chap doctors” or “quacks”. A Jhola 
chap doctor (medical salesman with shoulder bag) is 
an untrained and unlicensed medicine seller offering 
mainly curative services on an ambulatory basis. 
Ethical aspects: Ethical approval was obtained from the 
respective institutions (Rajendra Memorial Research 
Institute, Patna, India; Banaras Hindu University, 
Varanasi, India; International Centre of Diarrhoeal 
Disease Research in Dhaka, Bangladesh; Institute of 
Medicine, Tribhuvan University, Kathmandu, Nepal) 
as well as from the Ethical Review Committee, WHO/
TDR, Geneva, Switzerland.
Data analysis: Data were entered into Epi Info and 
analyzed using SPSS V.16.0. Continuous variables 
were summarized by means and medians as appropriate. 
Means were compared with t-tests, medians with the 
non-parametric Mann-Whitney test. Proportions were 
compared with Pearson’s Chi-square without continuity 
correction.
Results
 Table I shows the numbers of health care providers 
in each category; 219 providers from the informal sector 
and 102 from the formal sector were interviewed. Most 
informal healers were indigenous healers or so-called 
“quacks” (i.e., untrained members of the community 
practicing health care). The major proportion of ‘others’ 
in the Indian and Nepali sample of informal providers 
mainly reflects a high number of nurses delivering 
curative care on a for-profit basis. Roughly half of the 
formal providers belonged to the private and the other 
half to the public sector. 
 Overall, 82.6 per cent of providers were male, 91.3 
per cent in Vaishali, 68.5 per cent in Muzaffarpur, 87.8 
per cent in Nepal and 89.2 per cent in Bangladesh. There 
was no significant difference in sex between formal 
and informal providers in Vaishali, India and Nepal 
sites compared to a significantly higher proportion of 
male formal sector providers in Muzaffarpur, India 
(P<0.001) and informal sector male providers in 
Bangladesh (P<0.05). The mean age of providers was 
42.5 ± 10.1; 44.6 ± 10.62 in Vaishali, 43.9 ± 9.79 in 
Muzaffarpur, 38.1 ± 8.15 in Nepal and 42.8 ± 10.98 
yr in Bangladesh. The formal health care providers 
were on average 5 yr older than those of the informal 
sector, mean 45.9 vs 40.9 yr (P<0.001). The majority 
of the respondents had no formal qualifications, and 
their mean experience in the job was 13.4 ± 11.0 yr in 
Vaishali, 17.5 ± 8.5 in Muzaffarpur, 11.1 ± 6.9 in Nepal 
and 16.1 ± 9.4 yr in Bangladesh. The mean duration of 
experience was slightly but not significantly longer in 
the formal (15.5 yr) compared to the informal sector 
(14.5 yr).
 The absolute number of cases seen in the past year 
per provider ranged from 0 to 500, with the median 
number of kala-azar cases seen per provider varying 
from 1 in Bangladesh, to 2 in Vaishali, India and Nepal 
and 100 Muzaffarpur, India. Formal providers had seen 
a significantly higher number of kala-azar cases in the 
past year than informal providers, with a median of 6 
cases versus 3 in the latter group, (P=0.003; Mann-
Whitney). 
 Providers seemed well acquainted with the 
symptoms of VL, with 76.8 to 100.0 per cent correctly 
indicating fever as the main symptom and splenomegaly 
evoked by close to 90 per cent of providers in all 
countries, except for Bangladesh (52.3%). Bangladesh 
providers insisted on the darkening of skin as one of the 
main symptoms. There was no significant difference 
in the frequency with which the formal and informal 
providers evoked fever as a kala-azar symptom, 89.3 
versus 94.0 per cent, whereas a significantly higher 
Table I. Number (%) and category of health care providers enrolled in the study
Vaishali
India
Muzaffarpur
India
Mahottari
Nepal
Rajshahi
Bangladesh
Total
Informal: 55 (79.7) 57 (54.3) 69 (84.1) 38 (58.5) 219 (68.2)
Traditional healer 2 0 5 5 12
Chemist 12 0 18 2 32
Quacks 26 21 0 31 78
Others 15 36 46 0 97
Formal : 14 (20.3) 48 (45.7) 13 (15.9) 27 (41.5) 102 (31.8)
Private practitioner 5 32 6 5 48
Public sector 9 16 7 22 54
Total 69 (100.0) 105 (100.0) 82 (100.0) 65 (100.0) 321 (100.0)
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percentage of formal providers evoked splenomegaly 
as a sign, 79.6 vs. 63.8 per cent of informal providers, 
P=0.004.
 Table II shows the providers’ knowledge and 
practice related to kala-azar diagnosis. About 70 
per cent of Bangladesh providers established their 
diagnosis on purely clinical grounds, without any 
laboratory test, contrasting to only 11.6, 5.7, 9.7 per 
cent who did so respectively in Vaishali, Muzaffarpur 
and Nepal (P<0.001).
 Parasitological techniques as spleen biopsy and 
bone marrow aspirates were considered as the preferred 
test for kala-azar by 39.25 per cent of providers, with 
34.7 per cent in Vaishali, 51.4 per cent in Muzaffarpur, 
53.6 per cent in Nepal and 6.1 per cent in Bangladesh. 
The immunochromatographic test rK39 (or rK39 
strip test) was deemed the best test by 27.1 per cent 
of providers: 11.6 per cent in Vaishali, 48.6 per cent 
in Muzaffarpur, 24.4 per cent in Nepal and 12.3 per 
cent in Bangladesh, respectively. The most recent case 
was diagnosed by a rK39 strip test in 7.2 per cent of 
providers in Vaishali, 58.1 per cent in Muzaffarpur, 
45.1 per cent in Nepal and 4.6 per cent in Bangladesh. 
Overall, 39.8 per cent of formal providers used the 
rK39 strip test in the most recent diagnosis against 29.8 
per cent of informal providers (P<0.001).
 Table III shows the providers’ knowledge and 
practice related to kala-azar treatment. Knowledge 
of drugs varied strikingly. Miltefosin was known by 
2.0 per cent of providers in Vaishali, 27.2 per cent in 
Muzaffarpur, 27.2 per cent in Nepal and 18.5 per cent 
in Bangladesh. The main criteria for drug choice evoked 
by providers were the drug’s availability (66.1%) 
and its effectiveness (64.2%). Cost was an important 
determinant for drug choice in India and Bangladesh, 
and was cited by 35 to 50 per cent of providers, but less 
frequently in Nepal (10.5%), where the government was 
providing anti-VL drugs for free in the public sector.
Discussion
 This multi-country study of health providers’ 
knowledge and practice reflects the differences in 
disease burden and health system organization of the 
three countries. The high number of VL cases seen by 
providers in Muzaffarpur, India is consistent with the 
higher incidence of kala-azar in this country compared 
to Nepal12. 
 Provider knowledge on the newer tests and drugs 
was good in Muzaffarpur, in India, the epicentre of 
the current epidemic, and was much better than in the 
three other study sites. Given the major shortage of 
antileishmanial drugs and diagnostics in Bangladesh 
at the time of the study, it was not surprising that the 
providers there hardly knew any of these therapeutic 
innovations. The samples of providers were purposefully 
selected, and one should be cautious in comparing 
the data across countries, as the composition of these 
samples varied. Nonetheless, because of the built-in 
stratification we believe that the findings are fairly 
reflecting the spectrum of health provider practice in 
the region. Though it is hard to find any comparative 
data in the literature, the observed differences 
between countries are plausible given the contrasting 
epidemiological and health service context. 
 Qualitative research on kala-azar so far 
concentrated on the community perspective on the 
disease, usually showing a high level of awareness in 
areas with sustained epidemics. In Bihar, India, 97 per 
cent of the respondents in Kanti block, the epicentre 
of the ongoing epidemic, were aware of the disease, 
84 per cent could cite at least one symptom and 85 per 
cent knew it was a vector born disease8. The disease 
was perceived as more serious than malaria. Ahluwalia 
et al6 documented high awareness about kala-azar 
in a Bangladeshi community with an incidence rate 
of 2 per cent per year and 19 per cent case fatality 
amongst women, with rather good knowledge about 
disease causation. The demand for proper treatment 
and prevention of kala-azar was very high. In Nepal, 
Koirala et al7 found somewhat lower awareness 
about the disease, its causes and management in 
communities in Morang district, in a relatively recent 
outbreak. A recent multi-country study showed high 
awareness about the disease, with a high number of 
respondents in India (98%), Bangladesh (91%) and 
Nepal (82%) having heard about kala-azar. Fever 
as the leading symptom was identified by 92 per 
cent of interviewees in India, 72 per cent in Nepal, 
but only 30 per cent in Bangladesh. Likewise the 
knowledge about mosquitoes transmitting the disease 
was frequent in India (71%) and Nepal (88%) but 
almost absent in Bangladesh (21%)10. These data 
from qualitative research seem to indicate that the 
community awareness of the disease as well as the 
demand for treatment are high in those areas that 
are seriously afflicted by it, most likely because of 
its serious health and economic consequences. More 
detailed knowledge about transmission routes may 
be lower in areas that are relatively underserved or 
where the outbreak is of recent origin. Many authors 
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also emphasized the lack of access to proper VL care, 
in part due to huge economic barriers6,8,13,14. 
 In India, Singh et al8 showed how private providers 
were the first choice for seeking care for kala-azar, 
only a minority of community respondents indicated 
the governmental health services as their first choice. 
The main reasons evoked for avoiding public providers 
were the fear of toxic and ineffective drugs. Many 
public health facilities in Bihar continue till today to 
prescribe sodium stibogluconate, despite widespread 
drug resistance15 and a VL elimination programme that 
recommends miltefosin as the first-line drug. 
 In conclusion, this study shows a potential to 
involve the informal sector in case-finding, though 
innovative tools for VL care have not yet been fully 
taken up by private for profit care providers. However, 
a descriptive study as this one will by itself not diminish 
the knowledge gap among providers. VL elimination 
initiative in the region may consider these results to 
increase awareness of the VL problem. Short orientation 
programmes may be undertaken to update the knowledge 
of private physicians and paramedics. Further, it should 
be explored how these health providers can be more 
effectively involved. Given their substantial share in the 
care of VL patients, the VL elimination initiative will 
need to address the gaps in private provider’s knowledge 
while regulating their practice.
Conflict of interest: There is no conflict of interest.
Acknowledgment
 This study was funded by a grant from WHO/TDR’s - 
Implementation research programme.
References
1. http://searo.who.int/EN/Section10/Section2163_11668.htm, 
accessed on April 4, 2009. 
2. Singh SP, Reddy DCS, Rai M, Sundar S. Serious underreporting 
of visceral leishmaniasis through passive case reporting in 
Bihar, India. Trop Med Int Health 2006; 11 : 899-905.
3. Bhattacharya SK, Sur D, Sinha PK, Karbwang J. Elimination 
of leishmaniasis (kala-azar) from the Indian subcontinent is 
technically feasible & operationally achievable. Indian J Med 
Res 2006; 123 : 195-6.
4. Murray HW. Kala-azar - progress against a neglected disease. 
N Engl J Med 2002; 347 : 1793-4.
5. Boelaert M, Criel B, Leeuwenburg J, Van Damme W, Le Ray 
D, Van der Stuyft P. Visceral leishmaniasis control: a public 
health perspective. Trans R Soc Trop Med Hyg 2000; 94 : 465-
71.
6. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali 
M, et al. Visceral leishmaniasis: consequences of a neglected 
disease in a Bangladeshi community. Am J Trop Med Hyg 
2003; 69 : 624-8.
7. Koirala S, Parija SC, Karki P, Das ML. Knowledge, attitudes, 
and practices about kala-azar and its sandfly vector in rural 
communities of Nepal. Bull World Health Organ 1998; 76 : 
485-90.
8. Singh SP, Reddy DC, Mishra RN, Sundar S. Knowledge, 
attitude and practices related to kala-azar in a rural area of 
Bihar state, India. Am J Trop Med Hyg 2006; 75 : 505-8.
9. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, 
Kroeger A, et al. Implementation research to support the 
initiative on the elimination of kala azar from Bangladesh, 
India and Nepal - the challenges for diagnosis and treatment. 
Trop Med Int Health 2008; 13 : 2-5.
10. Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, et 
al. Visceral leishmaniasis elimination programme in India, 
Bangladesh, and Nepal: reshaping the case finding/case 
management strategy. PLoS Negl Trop Dis 2009; 3 : e355.
11. Moser CA, Kalton G. Survey methods in social investigation. 
London: Heinemann Educational Book; 1977.
12. Joshi A, Narain JP, Prasittisuk C, Bhatia R, Ghalib H, Alvar 
J, et al. Can visceral leishmaniasis be eliminated from Asia? 
J Vector Borne Dis 2008; 45 : 105-11.
13. Rijal S, Koirala S, Van der Stuyft P, Boelaert M. The economic 
burden of visceral leishmaniasis for households in Nepal. 
Trans R Soc Trop Med Hyg 2006; 100 : 838-41.
14. Meheus F, Boelaert M, Baltussen R, Sundar S. Costs of patient 
management of visceral leishmaniasis in Muzaffarpur, Bihar, 
India. Trop Med Int Health 2006; 11 : 1715-24.
15. Sundar S. Drug resistance in Indian visceral leishmaniasis. 
Trop Med Int Health 2001; 6 : 849-54.
Reprint requests: Dr Marleen Boelaert, Unit of Epidemiology and Disease Control, Institute of Tropical Medicine
 Nationalestraat 155, 2000 Antwerp, Belgium
 e-mail: mboelaert@itg.be
 KUMAR et al: PROVIDER SURVEY ON KALA-AZAR CARE 355
